AU2004249250C1 - Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases - Google Patents

Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases Download PDF

Info

Publication number
AU2004249250C1
AU2004249250C1 AU2004249250A AU2004249250A AU2004249250C1 AU 2004249250 C1 AU2004249250 C1 AU 2004249250C1 AU 2004249250 A AU2004249250 A AU 2004249250A AU 2004249250 A AU2004249250 A AU 2004249250A AU 2004249250 C1 AU2004249250 C1 AU 2004249250C1
Authority
AU
Australia
Prior art keywords
dioxo
benzamide
octahydro
ethenocycloprop
isoindol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2004249250A
Other languages
English (en)
Other versions
AU2004249250B2 (en
AU2004249250A1 (en
Inventor
Thomas R. Bailey
Robert Jordan
Susan R. Rippin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siga Technologies Inc
Original Assignee
Siga Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siga Technologies Inc filed Critical Siga Technologies Inc
Publication of AU2004249250A1 publication Critical patent/AU2004249250A1/en
Application granted granted Critical
Publication of AU2004249250B2 publication Critical patent/AU2004249250B2/en
Publication of AU2004249250C1 publication Critical patent/AU2004249250C1/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2004249250A 2003-06-20 2004-06-18 Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases Expired AU2004249250C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48018203P 2003-06-20 2003-06-20
US60/480,182 2003-06-20
PCT/US2004/019552 WO2004112718A2 (en) 2003-06-20 2004-06-18 Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2007351866A Division AU2007351866C1 (en) 2003-06-20 2007-04-23 Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases

Publications (3)

Publication Number Publication Date
AU2004249250A1 AU2004249250A1 (en) 2004-12-29
AU2004249250B2 AU2004249250B2 (en) 2011-09-01
AU2004249250C1 true AU2004249250C1 (en) 2012-04-12

Family

ID=33539267

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004249250A Expired AU2004249250C1 (en) 2003-06-20 2004-06-18 Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases

Country Status (11)

Country Link
EP (1) EP1638938B1 (enExample)
JP (2) JP4884216B2 (enExample)
AU (1) AU2004249250C1 (enExample)
BE (1) BE2022C521I2 (enExample)
CA (1) CA2529761C (enExample)
DK (1) DK1638938T3 (enExample)
ES (1) ES2632313T3 (enExample)
FR (1) FR22C1022I1 (enExample)
NL (1) NL301177I2 (enExample)
PL (1) PL1638938T3 (enExample)
WO (1) WO2004112718A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2529761C (en) * 2003-06-20 2013-08-13 Siga Technologies, Inc. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
AU2012268859B2 (en) * 2003-06-20 2016-05-05 Siga Technologies, Inc. Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
US7737168B2 (en) 2003-06-20 2010-06-15 Siga Technologies, Inc. Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
US8530509B2 (en) 2003-06-20 2013-09-10 Siga Technologies, Inc. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
KR101197672B1 (ko) * 2004-08-30 2012-11-07 얀센 파마슈티카 엔.브이. 11-베타 하이드록시스테로이드 데하이드로게나제저해제로서 트리사이클릭 락탐 유도체
US8410149B2 (en) 2004-12-06 2013-04-02 Siga Technologies Inc. Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses
CA2590962A1 (en) 2004-12-06 2006-06-15 Siga Technologies, Inc. Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses
US7994221B2 (en) 2004-12-06 2011-08-09 Siga Technologies, Inc. Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses
US8642577B2 (en) * 2005-04-08 2014-02-04 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
JP2008538354A (ja) * 2005-04-08 2008-10-23 キメリクス，インコーポレイテッド ウイルス感染症およびその他の内科疾患を治療するための化合物、組成物および方法
CN104758281A (zh) * 2007-04-23 2015-07-08 西佳技术公司 用于治疗和预防正痘病毒感染和相关疾病的化合物、组合物和方法
CN101977610B (zh) 2008-01-25 2012-05-16 奇默里克斯公司 治疗病毒感染的方法
WO2011011519A1 (en) 2009-07-21 2011-01-27 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
RU2412167C1 (ru) * 2009-12-02 2011-02-20 Федеральное государственное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФГУН ГНЦ ВБ "Вектор" Роспотребнадзора) {3,5-диоксо-4-азатетрацикло[5.3.2.02,6.08,10]додец-11-ен-4-ил}тиомочевина, обладающая противовирусной активностью в отношении ортопоксвирусов
RU2412168C1 (ru) * 2009-12-02 2011-02-20 Федеральное государственное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФГУН ГНЦ ВБ "Вектор" Роспотребнадзора) Гидрат n-{3,5-диоксо-4-азатетрацикло[5.3.2.02,6.08,10]додец-11-ен-4-ил}-2-гидроксибензамида, обладающий противовирусной активностью в отношении ортопоксвирусов
PT2534150T (pt) 2010-02-12 2017-05-02 Chimerix Inc Métodos para tratar uma infecção viral
KR20130018271A (ko) 2010-03-23 2013-02-20 시가 테크놀로지스, 인크. 다형체 형태 ｓｔ―２４６ 및 제조방법
US9278135B2 (en) 2010-04-26 2016-03-08 Chimerix Inc. Methods of treating retroviral infections and related dosage regimes
KR101868117B1 (ko) * 2010-08-05 2018-06-18 시가 테크놀로지스, 인크. Ｓｔ­246 액체 제형 및 방법
CN101906064A (zh) * 2010-08-09 2010-12-08 中国人民解放军军事医学科学院微生物流行病研究所 St-246的立体异构体的制备方法
RU2440983C1 (ru) * 2010-09-28 2012-01-27 Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) Метил, хлор и нитропроизводные n-{3, 5-диоксо-4-азатетрацикло[5.3.2.02,6.08,10]додец-11-ен-4-ил}-2-гидроксибензамида-противовирусные препараты, ингибирующие репликацию различных видов ортопоксвирусов
CA2882506C (en) 2012-08-16 2020-10-20 Siga Technologies, Inc. Methods of preparing tecovirimat
CA3128535C (en) * 2013-07-19 2024-10-15 Siga Technologies, Inc. PREPARATION OF AMORPHIC TECOVIRIMAT
JP2025510303A (ja) * 2022-03-27 2025-04-14 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ラノステロール合成酵素の低分子阻害剤
CN116730995B (zh) * 2022-08-12 2024-06-25 深圳微芯生物科技股份有限公司 一类酰肼类化合物、其制备方法及其应用
CN116003309B (zh) * 2022-08-12 2025-03-04 深圳微芯生物科技股份有限公司 一类酰肼类化合物、其制备方法及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2906755A (en) * 1956-11-16 1959-09-29 Schenley Ind Inc N-acyl derivatives of alpha-pyridine carboxylic acid hydrazide
WO2002067939A1 (en) * 2001-02-27 2002-09-06 Bristol-Myers Squibb Company Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4061763A (en) * 1975-05-09 1977-12-06 Merck & Co., Inc. Tricyclicdicarboximides
JPS5247844A (en) * 1975-10-15 1977-04-16 Ube Ind Ltd Elastomer compositions
JPS6483065A (en) * 1987-09-25 1989-03-28 Hitachi Chemical Co Ltd Endo-cis-3,6-cyclopropylene-tetra(or hexa)hydrophthalic acid imide derivative and antiarhythmic agent
US5068356A (en) * 1990-02-20 1991-11-26 Atochem North America, Inc. Hindered phenolic n-(amido)imides
US6433016B1 (en) * 2001-01-12 2002-08-13 Vassil Stefanov Georgiev Drugs for treating viral infections
US6596771B2 (en) 2001-01-12 2003-07-22 Schering Corporation Drugs for treating viral infections
CA2529761C (en) * 2003-06-20 2013-08-13 Siga Technologies, Inc. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2906755A (en) * 1956-11-16 1959-09-29 Schenley Ind Inc N-acyl derivatives of alpha-pyridine carboxylic acid hydrazide
WO2002067939A1 (en) * 2001-02-27 2002-09-06 Bristol-Myers Squibb Company Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
BLUMEL, J. et al., Chemische Berichte, 1993, vol. 126, pages 1283-1290 *
CAS RN 316383-22-9 *
CAS RN 329362-05-2 *
CAS RN 329368-29-8 *
CAS RN 329717-02-4 *
CAS RN 329775-41-9 *
CAS RN 329912-01-8 *
CAS RN 331632-70-3 *
CAS RN 340982-60-7 *
CAS RN 432022-16-7 *
CAS RN 432022-17-8 *
CAS RN 488821-91-6 *
CAS RN 492426-98-9 *
CAS RN 492455-97-7 *
FUJIMOTO, M. et al., Chemical Abstracts, 1965, vol. 62, abstract no. 529g *
ISHITOBI, H. et al., Bulletin of the Chemical Society of Japan, 1971, vol. 44, pages 2993-3000 *
KOHLER, E.P. et al., Journal of the American Chemical Society, 1939, vol. 61, pages 1057-1061 *
KURTZ, D.W. et al., Journal of Chemical Education, 1989, vol. 66, pages 873-874 *
SCHUELER, P.E. et al., Journal of Organic Chemistry, 1974, vol. 39, pages 2063-2069 *
VERMA, S.M. et al., Recueil, Journal of the Royal Netherlands Chemical Society, 1978, vol. 97, pages 238-241 *

Also Published As

Publication number Publication date
JP5657489B2 (ja) 2015-01-21
JP2011252019A (ja) 2011-12-15
ES2632313T3 (es) 2017-09-12
NL301177I1 (nl) 2022-06-08
WO2004112718A2 (en) 2004-12-29
EP1638938A4 (en) 2008-09-17
CA2529761C (en) 2013-08-13
EP1638938A2 (en) 2006-03-29
DK1638938T3 (en) 2017-07-31
JP4884216B2 (ja) 2012-02-29
AU2004249250B2 (en) 2011-09-01
BE2022C521I2 (enExample) 2024-04-23
CA2529761A1 (en) 2004-12-29
PL1638938T3 (pl) 2017-10-31
NL301177I2 (nl) 2022-08-23
FR22C1022I1 (fr) 2022-07-22
JP2007521273A (ja) 2007-08-02
EP1638938B1 (en) 2017-04-12
WO2004112718A3 (en) 2005-04-07
AU2004249250A1 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
AU2004249250B2 (en) Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
US8039504B2 (en) Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
US8124643B2 (en) Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
US7687641B2 (en) Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
US9045418B2 (en) Compounds, compositions and methods for treatment and prevention of Orthopoxvirus infections and associated diseases
AU2012268859B2 (en) Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
AU2016208315A1 (en) Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 30 NOV 2011.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 30 NOV 2011

FGA Letters patent sealed or granted (standard patent)